Stock ALNEV NEOVACS
Add to a list
To use this feature you must be a member
Log inSign up

Financials NEOVACS Euronext Paris

Equities

ALNEV

FR001400HDX0

Biotechnology & Medical Research

End-of-day quote Euronext Paris
Other stock markets
 06:00:00 2024-02-04 pm EST 		5-day change 1st Jan Change
1.98 EUR -1.00% Intraday chart for NEOVACS -1.00% -1.00%

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 - - - - - -
Enterprise Value (EV) 1 - - - - - -
P/E ratio - - - - - -
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA - - - - - -
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book - - - - - -
Nbr of stocks (in thousands) - - - - - -
Reference price 2 36,800,000 16,240,000 4,640,000 2,416,000 40,000 336,000
Announcement Date 4/27/18 4/29/19 4/30/20 6/29/21 5/2/22 4/30/23
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 0.0128 0.007 0.0952 0.031 0.0225 0.001112
EBITDA 1 -18.27 -13.02 -8.118 -3.437 -7.728 -6.294
EBIT 1 -18.33 -13.08 -8.175 -3.492 -7.828 -6.445
Operating Margin -142,818.7% -186,852.84% -8,590.87% -11,281.43% -34,725.65% -579,583.27%
Earnings before Tax (EBT) 1 -18.86 -13.56 -9.302 -6.684 -12.48 -4.346
Net income 1 -14.84 -10.78 -7.548 -6.143 -11.84 -3.549
Net margin -115,618.2% -154,006.91% -7,932.63% -19,846.4% -52,512.21% -319,109.98%
EPS - - - - - -
Free Cash Flow 1 -11.45 -11.26 -6.032 -2.054 -3.701 -3.496
FCF margin -89,234.18% -160,809.06% -6,339.21% -6,635% -16,418.4% -314,371.22%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/27/18 4/29/19 4/30/20 6/29/21 5/2/22 4/30/23
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 2.7 1.35 1.23 9.68 32.1 5.55
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -11.5 -11.3 -6.03 -2.05 -3.7 -3.5
ROE (net income / shareholders' equity) -1,010% -606% -287% -88.7% -43.1% -7.54%
ROA (Net income/ Total Assets) -105% -85.2% -68.7% -20.6% -15.8% -7.76%
Assets 1 14.15 12.65 10.98 29.78 75.11 45.74
Book Value Per Share - - - - - -
Cash Flow per Share - - - - - -
Capex 1 0.13 0.01 0 0.21 0.35 0.15
Capex / Sales 1,013.57% 143.6% 2.47% 668.63% 1,547.6% 13,736.33%
Announcement Date 4/27/18 4/29/19 4/30/20 6/29/21 5/2/22 4/30/23
1EUR in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALNEV Stock
  4. ALNEV Stock
  5. Financials NEOVACS